Alto Neuroscience (ANRO) News
NYSE: ANROHealth CareBiotechnology: Pharmaceutical PreparationsUSD
25.37-1.14 (-4.30%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ANRO news summary
We found 5 recent headlines mentioning Alto Neuroscience (ANRO): 1 in the past week and 3 in the past 30 days, most often from Nasdaq, Seeking Alpha, Business Wire. For price context, ANRO is down 4.30% at $25.37. The most recent story, "Is UnitedHealth Group (UNH) Stock Outpacing Its Medical Peers This Year?", was published by Nasdaq on Nov 17, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Alto Neuroscience headlines
- Is UnitedHealth Group (UNH) Stock Outpacing Its Medical Peers This Year?Here is how UnitedHealth Group (UNH) and Alto Neuroscience, Inc. (ANRO) have performed compared to their sector so far this year.NasdaqUNH, ANRO
- Alto Neuroscience GAAP EPS of -$0.54 beats by $0.13Seeking Alpha
- Alto Neuroscience Reports Third Quarter 2026 Financial Results and Recent Business HighlightsMOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision…Business Wire
- Here's Why You Should Add ANRO Stock to Your Portfolio NowAlto advances its depression drug pipeline, with key 2027 study results ahead for ALTO-207, ALTO-300 and ALTO-100.NasdaqANRO, AMRN, CORT, ALDX
- Are Medical Stocks Lagging Cardinal Health (CAH) This Year?Here is how Cardinal Health (CAH) and Alto Neuroscience, Inc. (ANRO) have performed compared to their sector so far this year.NasdaqCAH, ANRO